Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies

L Sordo, G Barrio, MJ Bravo, BI Indave, L Degenhardt… - bmj, 2017 - bmj.com
Objective To compare the risk for all cause and overdose mortality in people with opioid
dependence during and after substitution treatment with methadone or buprenorphine and …

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a …

T Vos, RM Barber, B Bell, A Bertozzi-Villa, S Biryukov… - The lancet, 2015 - thelancet.com
Background Up-to-date evidence about levels and trends in disease and injury incidence,
prevalence, and years lived with disability (YLDs) is an essential input into global, regional …

Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta …

T Santo, B Clark, M Hickman, J Grebely… - JAMA …, 2021 - jamanetwork.com
Importance Mortality among people with opioid dependence is higher than that of the
general population. Opioid agonist treatment (OAT) is an effective treatment for opioid …

The burden of opioid-related mortality in the United States

T Gomes, M Tadrous, MM Mamdani… - JAMA network …, 2018 - jamanetwork.com
Importance Opioid prescribing and overdose are leading public health problems in North
America, yet the precise public health burden has not been quantified. Objective To examine …

The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010

HA Whiteford, AJ Ferrari, L Degenhardt, V Feigin… - PloS one, 2015 - journals.plos.org
Background The Global Burden of Disease Study 2010 (GBD 2010), estimated that a
substantial proportion of the world's disease burden came from mental, neurological and …

The increasing global health priority of substance use in young people

L Degenhardt, E Stockings, G Patton, WD Hall… - The Lancet …, 2016 - thelancet.com
Substance use in young people (aged 10–24 years) might disrupt key periods of transition
that occur as the adolescent brain undergoes cognitive and emotional development, and …

A heavy burden on young minds: the global burden of mental and substance use disorders in children and youth

HE Erskine, TE Moffitt, WE Copeland… - Psychological …, 2015 - cambridge.org
BackgroundMental and substance use disorders are common and often persistent, with
many emerging in early life. Compared to adult mental and substance use disorders, the …

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

BR Haight, SM Learned, CM Laffont, PJ Fudala, Y Zhao… - The Lancet, 2019 - thelancet.com
Background RBP-6000, referred to as BUP-XR (extended-release buprenorphine), is a
subcutaneously injected, monthly buprenorphine treatment for opioid use disorder. BUP-XR …

Modelling the combined impact of interventions in averting deaths during a synthetic‐opioid overdose epidemic

MA Irvine, M Kuo, JA Buxton, R Balshaw… - …, 2019 - Wiley Online Library
Background and aims The province of British Columbia (BC) Canada has experienced a
rapid increase in illicit drug overdoses and deaths during the last 4 years, with a provincial …

Extended‐release injectable naltrexone for opioid use disorder: a systematic review

BP Jarvis, AF Holtyn, S Subramaniam, DA Tompkins… - …, 2018 - Wiley Online Library
Aims To review systematically the published literature on extended‐release naltrexone (XR‐
NTX, Vivitrol®), marketed as a once‐per‐month injection product to treat opioid use …